The present invention is directed to previously identified inhibitors ofcAMP efflux (ICE) and their use in feaiing/niasking body odor, inhibiting, reducing and/or eliminating hyperhidrosis (excessive sweating), tanning skin or protecting skin before and/or after exposure to the sun as well as.for treating certain skin conditions, in one embodiment, the invention provides a method for inhibiting body odor, a condition that is characterized by an unpleasant odor from the products of the microbial sweat degradation. By inhibiting the efflux of the precursor compounds that are degraded, novel compounds are- capable of preventing unwanted odors. Deodorant compositions that employ this new approach for the control of bodily odor are provided, ICE compounds can also be used as. components, of cosmetic formulations including tanning and after-sun formulations, formulations for skin conditions as described herein and other cosmetic formulations.
A61K 8/18 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition
A61K 45/08 - Mélanges d'un ingrédient actif et d'une substance auxiliaire, ni l'un ni l'autre n'étant chimiquement caractérisés, p. ex. antihistaminique et agent tensio-actif
A61P 17/00 - Médicaments pour le traitement des troubles dermatologiques
A61Q 17/04 - Préparations topiques pour faire écran au soleil ou aux radiationsPréparations topiques pour bronzer
A61Q 19/00 - Préparations pour les soins de la peau
2.
SYSTEM AND METHOD FOR DETERMINING A PHOTON STATISTIC MEASUREMENT OF A PULSED LIGHT SOURCE USING AN UNBALANCED BEAMSPLITTER
A method and system for determining a photon statistics of a light source using an unbalanced beam-splitter is disclosed. The method includes collecting data for photon counts for a first output path and a second output path by a first detector and a second detector, respectively, for a first time period, a first power level, and a first characteristic and collecting data for photon counts for the first output path and the second output path by the first detector and the second detector, respectively, for a second time period, a second power level, and a second characteristic; and processing outputs of the first and the second detector to determine the photon statistics.
A privacy-preserving, mutual PUF-based authentication protocol that uses soft data to exchange and correlate Helper Data bitstrings instead of PUF response bitstrings as a means of authenticating chips to prevent attacks.
H04L 9/32 - Dispositions pour les communications secrètes ou protégéesProtocoles réseaux de sécurité comprenant des moyens pour vérifier l'identité ou l'autorisation d'un utilisateur du système
G06F 21/73 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information par création ou détermination de l’identification de la machine, p. ex. numéros de série
5.
Supported Ni-M materials for electrooxidation of hydrazine
A supported bi-metallic non-platinum catalyst that is capable of oxidizing hydrazine to produce, as by-products of energy production, nitrogen, water, and zero or near-zero levels of ammonia is described. The catalyst is suitable for use in fuel cells, particularly those that utilizes an anion-exchange membrane and a liquid fuel such as hydrazine.
H01M 4/90 - Emploi de matériau catalytique spécifié
H01M 8/22 - Éléments à combustible dans lesquels le combustible est à base de matériaux comprenant du carbone, de l'oxygène ou de l'hydrogène et d'autres élémentsÉléments à combustible dans lesquels le combustible est à base de matériaux comprenant uniquement des éléments autres que le carbone, l'oxygène ou l'hydrogène
6.
METHOD AND SYSTEM FOR IN-LINE OPTICAL SCATTEROMETRY
NA11 NA22 NA22 NA11 1 ; additional optical components configured to receive the optical beam reflected from the sample surface and to focus the reflected beam onto a detector; and a recording system to record the reflectivity of the sample surface as a function of the angle of incidence.
The present invention is directed to the discovery that RapI-GTP, Racl-GTP and Flt3-L can be used as Biomarkers for the early detection of sepsis in patients suspected of a bacterial infection which presents as sepsis or is likely to produce sepsis. In particular, the present invention is directed to methods, assays and kits which may be used to distinguish sepsis (infection) from systematic inflammatory response caused by sterile inflammation in trauma patients. The method may he used to diagnose bacteria infection and/or sepsis and monitor therapy of a patient to allow modification of treatment and/or cessation of treatment.
C12Q 1/04 - Détermination de la présence ou du type de micro-organismeEmploi de milieux sélectifs pour tester des antibiotiques ou des bactéricidesCompositions à cet effet contenant un indicateur chimique
C12Q 1/18 - Test de l'activité antimicrobienne d'un matériau
G01N 33/483 - Analyse physique de matériau biologique
8.
DISCOVERY OF NOVEL MOLECULES AND REPURPOSED DRUGS FOR RAS FAMILY GTPASES
THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (USA)
Inventeur(s)
Sklar, Larry A.
Oprea, Tudor I.
Waller, Anna
Wandinger-Ness, Angela
Haynes, Mark K.
Campbell, Sharon
Ames, Harold, A.
Abrégé
The present invention is directed to compounds, compositions and methods for modulating RAS family GTPases, in particular KRas, HRas and NRas GTPases. These GTPases are upregulated in cancer and in other tissue and represent appropriate targets for therapy. Methods for identifying the activity of compounds with respect to these and other GTPases in multiplex flow cytometry systems represents another aspect of this invention.
A61K 31/196 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe amino le groupe amino étant lié directement à un cycle, p. ex. acide anthranilique, acide méfénamique, diclofénac, chlorambucil
A61K 31/618 - Acide salicyliqueSes dérivés ayant le groupe carboxyle en position 1 estérifié, p. ex. salsalate
An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p. ex. émulsion, particule, complexe d’inclusion, stent ou kit
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
The present invention is directed to a system and methods of predicting undiagnosed mental disorders in a patient and determining the best medication-class treatment for the mental disorder through the analysis of functional magnetic resonance imaging of functional connectivity of the brain representative of a certain mental disorder.
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p. ex. formation d'images par résonance magnétique
G06T 7/45 - Analyse de la texture basée sur la description statistique de texture utilisant un calcul de matrice de cooccurrence
A diagnostic transdermal patch which utilizes a microneedle array and an integrated biochemical assay to detect the presence of biomolecules which are associated with a specific condition or disease, such as mild traumatic brain injury (MTBI).
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61B 10/00 - Instruments pour le prélèvement d'échantillons corporels à des fins de diagnostic Autres procédés ou instruments pour le diagnostic, p. ex. pour le diagnostic de vaccination ou la détermination du sexe ou de la période d'ovulationInstruments pour gratter la gorge
An auto-injection system is having an injector, one or more sensors, and a controller, the controller activates the injector when the sensors detect a predetermined condition.
A61M 5/142 - Perfusion sous pression, p. ex. utilisant des pompes
A61M 5/20 - Seringues automatiques, p. ex. avec tige de piston actionnée automatiquement, avec injection automatique de l'aiguille, à remplissage automatique
13.
COMPOSITIONS AND METHODS FOR TREATING HEMORRHAGIC STROKE
A pharmaceutical composition includes a ferrochelatase inhibitor and a pharmaceutically acceptable carrier. In another aspect, a method of treating a subject having, or a t risk of having, a hemorrhagic stroke generally includes administering to the subject a pharmaceutical composition that includes a ferrochelatase inhibitor in an amount effective to ameliorate at least one symptom or clinical sign of hemorrhagic stroke.
A61K 31/395 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines
A61K 31/409 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p. ex. sulpiride, succinimide, tolmétine, buflomédil ayant quatre de ces cycles, p. ex. dérivés de la porphine, bilirubine, biliverdine
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
14.
TECHNOLOGIES FOR ENERGY-MODULATED RADIATION THERAPY
Described are devices, systems, and methods for modulating the spectral energy distribution produced by an x-ray source via control of the energy of the x-ray-generating electron beam, e.g., for energy-modulated radiation therapy or other purposes. In some embodiments, such energy modulation is achieved by an add-on device to a linear accelerator. Also disclosed are computational methods and computer program products for planning energy-modulated therapy.
The present invention is directed to a system and methods of predicting protein function through a process of encoding protein structural information into a computer readable format and the use of a convolutional neural network designed to recognize such encoded format.
The present invention is directed to the discovery that Galectins and in particular, Galectin-8 and Galectin-9 control mTor response (Galectin-8 is a mTOR inhibitor and Galectin-9 is modulator/upregulator of AMPKinase) to endomembrane damage and these compositions can be used, either alone or together, optionally in combination with a lysomotropic agent and other bioactive agents as compositions for the treatment of autophagy-related diseases. The present invention is directed to pharmaceutical compositions and methods for treating autophagy-related diseases as described herein.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A61K 31/7004 - Monosaccharides ayant uniquement des atomes de carbone, d'hydrogène et d'oxygène
A61K 31/7016 - Disaccharides, p. ex. lactose, lactulose
A61K 31/702 - Oligosaccharides, c.-à-d. ayant trois à cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiques
A61K 31/715 - Polysaccharides, c.-à-d. ayant plus de cinq radicaux saccharide liés les uns aux autres par des liaisons glycosidiquesLeurs dérivés, p. ex. éthers, esters
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
Provided is a composite metal-wide-bandgap semiconductor tip for scanning tunneling microscopy and/or scanning, tunneling lithography, a method of forming, and a method for using the composite metal-wide-bandgap semiconductor tip.
G01Q 60/16 - Sondes, leur fabrication ou leur instrumentation correspondante, p. ex. supports
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
G01Q 80/00 - Applications des techniques de sonde à balayage, autres que les techniques SPM
G03F 7/00 - Production par voie photomécanique, p. ex. photolithographique, de surfaces texturées, p. ex. surfaces impriméesMatériaux à cet effet, p. ex. comportant des photoréservesAppareillages spécialement adaptés à cet effet
18.
SILICIFIED CELL REPLICAS, METHODS OF MAKING, AND METHODS OF USING
A silicified cell replica includes a silicified cell or a silicified subcellular fragment. The silicified cell replica may be used to induce an immunological response, treat a bacterial infection, or treat a patient with cancer.
A61K 35/12 - Substances provenant de mammifèresCompositions comprenant des tissus ou des cellules non spécifiésCompositions comprenant des cellules souches non embryonnairesCellules génétiquement modifiées
A61K 35/13 - Cellules tumorales, quel que soit le tissu d’origine
A composition includes two or more isoflavone compounds and a pharmaceutically acceptable carrier. In some cases, the isoflavone compounds can include calycosin, formononetin, or daidzein. The composition can be used in methods to treat a subject having at risk of having cerebral ischemia-reperfusion injury and/or hypoxia brain injury.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p. ex. cannabinols, méthanthéline
A61P 9/00 - Médicaments pour le traitement des troubles du système cardiovasculaire
A61P 9/10 - Médicaments pour le traitement des troubles du système cardiovasculaire des maladies ischémiques ou athéroscléreuses, p. ex. médicaments antiangineux, vasodilatateurs coronariens, médicaments pour le traitement de l'infarctus du myocarde, de la rétinopathie, de l'insuffisance cérébro-vasculaire, de l'artériosclérose rénale
A61P 25/10 - AntiépileptiquesAnticonvulsivants pour le traitement du petit-mal
Provided is a spectral sensor array, including: a planar waveguide on a substrate; a chirped input coupling grating, wherein the chirped input coupling grating comprises a transverse chirp to provide a spectrally selective coupling of incident light into the planar waveguide; an output coupling grating; and an array of photodetectors arranged to receive the light coupled out of the waveguide.
G01J 3/24 - Production du spectreMonochromateurs en utilisant des éléments diffractants, p. ex. réseaux en utilisant des réseaux profilés de façon à favoriser un ordre particulier
G02B 6/10 - Guides de lumièreDétails de structure de dispositions comprenant des guides de lumière et d'autres éléments optiques, p. ex. des moyens de couplage du type guide d'ondes optiques
22.
Accelerated precomputation of reduced deformable models
Technologies are disclosed for precomputation of reduced deformable models. In such precomputation, a Krylov subspace iteration may be used to construct a series of inertia modes for an input mesh. The inertia modes may be condensed into a mode matrix. A set of cubature points may be sampled from the input mesh, and cubature weights of the set of cubature points may be calculated for each of the inertia modes in the mode matrix. A training dataset may be generated by iteratively adding training samples to the training dataset until a training error metric converges, wherein each training sample is generated from an inertia mode in the mode matrix and corresponding cubature weights. The reduced deformable model may be generated, including inertia modes in the training dataset and corresponding cubature weights.
In one aspect, a fusion antibody specifically binds to a C. difficile virulence toxin. In some embodiments, the C. difficile virulence toxin can include TcdA or TcdB. In some embodiments, the fusion antibody can include a first antibody moiety and a second antibody moiety. The first antibody moiety can include at least a fragment of a first antibody, and the second antibody moiety can include at least a fragment of a second antibody. In another aspect, a recombinant cell expresses the fusion antibody. In another aspect, a recombinant cell has activity that can be modulated by growing the recombinant cell in medium that includes cellobiose. Generally, the recombinant cell includes a heterologous polynucleotide that includes a promoter operably linked to a heterologous coding region, wherein the expression from the promoter is modulated when the recombinant cell is grown in culture medium that comprises cellobiose compared to when the recombinant cell is grown in culture medium that comprises glucose.
An apparatus tor determining a position of an object inside a body includes a first, detector configured to receive a signal from the object inside the body. The apparatus also includes a camera configured to capture m image or video of outside of a portion of the body, The object is positioned inside the portion of the body. A connoting system is configured to receive the signal from the first detector and the image or video from the camera and to determine the position of the object Inside the body. A screen, is configured to display die position of the object inside the body.
A61B 5/06 - Dispositifs autres que ceux à radiation, pour détecter ou localiser les corps étrangers
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
A61M 25/095 - Dispositions pour permettre la détection de la position interne du cathéter, p. ex. à l'aide d'une radiographie
25.
ATOMIC FORCE MICROSCOPY BASED ON NANOWIRE TIPS FOR HIGH ASPECT RATIO NANOSCALE METROLOGY/CONFOCAL MICROSCOPY
Nanowires that may be utilized in microscopy, for example atomic force microscopy (AFM), as part of an AFM probe, as well as for other uses, are disclosed. The nanowires may be formed from a Group III nitride such as an epitaxial layer that may be or include gallium nitride, indium nitride, aluminum nitride, and an alloy of these materials. During use of the AFM probe to measure a topography of a test sample surface, the nanowire can activated and caused to lase and emit a light, thereby illuminating the surface with the light. In an implementation, the light can be collected by the AFM probe itself, for example through an optical fiber to which the nanowire is attached.
G01Q 60/06 - Microscopie optique à champ proche à balayage SNOM [Scanning Near-Field Optical Microscopy] combinée avec la microscopie à forces atomiques AFM [Atomic Force Microscopy]
G01Q 60/38 - Sondes, leur fabrication ou leur instrumentation correspondante, p. ex. supports
B82Y 35/00 - Procédés ou appareils pour la mesure ou l’analyse des nanostructures
26.
Quantitative [Fe]-MRI (femri) of anti-PSMA-conjugated SPIONs based on PSMA expression levels
2-weighted images into a set of contrast images which are subtracted from each other to yield a contrast difference image proportional to the concentration of the magnetic material.
G01R 33/56 - Amélioration ou correction de l'image, p. ex. par des techniques de soustraction ou d'établissement de moyenne
G01R 33/465 - Spectroscopie RMN appliquée à du matériau biologique, p. ex. tests in vitro
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
Apparatus, systems, and methods of operating a fiber laser having polarization-preserving fibers can be applied as a sensor to detect a physical quantity. In various embodiments, polarization-preserving fibers can provide a laser cavity having an interferometer disposed in the laser cavity. In various embodiments, a fiber optical parametric oscillator can include an interferometer disposed in the cavity of the optical parametric oscillator. Additional apparatus, systems, and methods are disclosed.
H01S 3/106 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de dispositifs placés dans la cavité
H01S 3/108 - Commande de l'intensité, de la fréquence, de la phase, de la polarisation ou de la direction du rayonnement, p. ex. commutation, ouverture de porte, modulation ou démodulation par commande de dispositifs placés dans la cavité utilisant des dispositifs optiques non linéaires, p. ex. produisant une diffusion par effet Brillouin ou Raman
G02F 1/39 - Optique non linéaire pour la génération ou l'amplification paramétrique de la lumière, des infrarouges ou des ultraviolets
H01S 3/086 - Structure ou forme des résonateurs optiques ou de leurs composants un ou plusieurs réflecteurs ayant des propriétés ou positions variables pour le réglage initial du résonateur
28.
RUGGED, SINGLE CRYSTAL WIDE-BAND-GAP-MATERIAL-SCANNING-TUNNELING MICROSCOPY/LITHOGRAPHY TIPS
Provided is a composite metal-wide-bandgap semiconductor tip for scanning tunneling microscopy and/or scanning, tunneling lithography, a method of forming, and a method for using the composite metal-wide-bandgap semiconductor tip.
Tie present invention relates to compositions and methods of influencing autophagy by modulating TRIM (tripartite motif containing) proteins, especially TRIM 8, TRIM: 10, TRIM 16, TRIM 19 and/or TRI.M 51 (preferably TRIM 16} and galectins, especially galectins 3 m order to influence authophagy and treat a number of disease states and/or conditions which are mediated and/or influenced by autophagy, including inflammatory disease states and/or conditions, including a microbial infection such as a Mycobacterium infection, among numerous others, an inflammatory disorder, a lysosomal, storage disorder, an immune disorder, a neurodegenerative disorder and a cancer.
A detector or sensor including a transistor having a sensor element that generates a current when exposed to a stimulus such as light or a chemical, in one implementation, the sensor element is positioned between a transistor gate and a transistor channel. When the sensor element is not being exposed to the stimulus, the transistor outputs a first voltage on a transistor drain contact when the transistor Inverts. When the sensor element is being exposed to the stimulus, the transistor outputs a second voltage on the transistor drain contact when the transistor inverts, where the second voltage is higher than the first voltage.
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
H01L 31/04 - Dispositifs à semi-conducteurs sensibles aux rayons infrarouges, à la lumière, au rayonnement électromagnétique d'ondes plus courtes, ou au rayonnement corpusculaire, et spécialement adaptés, soit comme convertisseurs de l'énergie dudit rayonnement e; Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives; Leurs détails adaptés comme dispositifs de conversion photovoltaïque [PV]
H01L 31/18 - Procédés ou appareils spécialement adaptés à la fabrication ou au traitement de ces dispositifs ou de leurs parties constitutives
This disclosure describes detecting genetically distinct kinds of inherited myopathies in horses, variously referred to as Polysaccharide Storage Myopathy type 2 (PSSM2), Myofibrillar Myopathy (MFM), or idiopathic myopathy.
G01N 33/48 - Matériau biologique, p. ex. sang, urineHémocytomètres
C07H 21/04 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p. ex. acides nucléiques avec le désoxyribosyle comme radical saccharide
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12N 15/12 - Gènes codant pour des protéines animales
A61D 99/00 - Matière non prévue dans les autres groupes de la présente sous-classe
32.
VLP-BASED VACCINES FOR TARGETING STAPHYLOCOCCUS AUREUS SECRETED VIRULENCE FACTORS
The present invention is directed to virus-like particles (VLPs) which are engineered to present epitopes from Staphylococcus aureus (SA), preferably autoinducing peptides (AIPs) which regulate quorum-sensing dependent virulence in this pathogen, or epitopes from SA toxins and leukocidins. These VLPs may be used to provide immunogenic compositions and efficacious vaccines. In a mouse model of SA dermonecrosis, vaccination with AIP-containing VLPs or SA toxin-containing VLPs induces protective immunity to limit the pathogenesis of SA infection and promote bacterial clearance.
The present invention is directed to the use of compounds which are modulators of the G protein-Coupled Estrogen Receptor (GPER) for the inhibition -and/or treatment of Bacterial infections, especially including metMctHin-resistant Staphylococcus aureus (MRSA) infections. Pharmaceutical compositions and methods of treatment of bac terial pathogens, including MRSA are also described.
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
This disclosure describes, in one aspect, a method of electric-field-assisted nucleotide sequencing. Generally, the method includes performing an ion-sensitive nucleotide sequencing method, applying an electric field across the device while the nucleotide sequencing reactions are being performed so that ions released by the sequencing reactions are directed to contact with the ion-sensitive detector, and detecting at least a portion of the released ions in contact with the ion-sensitive detector.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
G01N 27/414 - Transistors à effet de champ sensibles aux ions ou chimiques, c.-à-d. ISFETS ou CHEMFETS
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
The present prevention provides a surface coating for cooling a surface by light scattering comprising a plurality of successive layers, each of the layers may be comprised of a plurality of spheres arranged to form a structure comprised of packed spheres. Each layer may have a different arrangement of packed spheres to create to a different light scattering property in each of the layers. The coating of the structures may also be formed by randomly packed spheres and the spheres may have a uniform diameter.
This disclosure describes compositions, vaccine, and methods that involve a biocomposite material Generally, the biocomposite material includes a cell and a lipid-silica matrix at least partially encapsulating the cell. In some cases, the cell can be viable but not culturable (VBNC). In some cases, the lipid-silica matrix includes a dried sol and/or possesses ordered nanostructure.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 9/26 - Particules distinctes dans une matrice support
C12N 11/04 - Enzymes ou cellules microbiennes immobilisées sur ou dans un support organique piégées à l’intérieur du support, p. ex. dans un gel ou dans des fibres creuses
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
37.
ELECTRICALLY AND THERMALLY CONDUCTIVE POLYMER CONCRETE
An electrically and thermally conductive polymer concrete (made of a polymer and aggregate particles without cement) comprising non-functionalized nanoparticles (e.g. non-functionalized multi-walled carbon nanotubes (NF-MWCNTs), non-functionalized carbon nanofibers, non-functionalized nanoalumina) dispersed therein and methods of making same.
B82B 1/00 - Nanostructures formées par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
38.
HUMAN GLUT5 SPECIFIC INHIBITORS AND METHODS OF TREATMENT
The present invention relates to compounds which have been discovered to be potent ligands (inhibitors) of human GLUT5 (glucose transporter type 5), a facilitative glucose transporter that transports fructose, and their use as ligands assays which can uncover additional ligands of GLUT5, having the potential for being used as drugs. In addition, the present invention is directed to compounds, chemical compositions and methods for treating disease states and conditions which are mediated through GLUT5, including such disease states and conditions as GLUT5 deficiency syndrome, diabetes (type I and II), cancer, metabolic diseases including metabolic syndrome and fatty liver disease, among others.
C07D 317/48 - Méthylènedioxybenzènes ou méthylènedioxybenzènes hydrogénés, non substitués sur l'hétérocycle
C07D 319/08 - Dioxanes-1, 3Dioxanes-1, 3 hydrogénés condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 321/10 - Cycles à sept chaînons condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 405/12 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07C 309/46 - Acides sulfoniques ayant des groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons d'un squelette carboné contenant des atomes d'azote, ne faisant pas partie de groupes nitro ou nitroso, liés au squelette carboné ayant les groupes sulfo liés à des atomes de carbone de cycles aromatiques à six chaînons non condensés
A61K 31/357 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant plusieurs atomes d'oxygène dans le même cycle, p. ex. éthers en couronne, guanadrel
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
39.
Toroidal mesoporous silica nanoparticles (TMSNPs) and related protocells
National Technology & Engineering Solutions of Sandia, LLC (USA)
Inventeur(s)
Brinker, C. Jeffrey
Lin, Yu-Shen
Abrégé
In one aspect, the invention provides novel monodisperse, colloidally-stable, toroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia basecatalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C12N 15/88 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation utilisant la micro-encapsulation, p. ex. utilisant des vésicules liposomiques
B82Y 15/00 - Nanotechnologie pour l’interaction, la détection ou l'actionnement, p. ex. points quantiques comme marqueurs en dosages protéiques ou moteurs moléculaires
40.
COMPOSITIONS AND METHODS FOR CONTROL OF VECTOR-BORNE DISEASE
This disclosure describes a genetically-modified microbe that is a symbiont of an animal that is a vector organism for a pathogenic microbe, a paratransgenic organism that includes the genetically-modified microbe, and methods involving use of the genetically-modified microbe and/or the paratransgenic organism. Generally, the genetically-modified microbe includes a heterologous polynucleotide that encodes a heterologous polypeptide that reduces transmission of the pathogenic microbe.
C12N 1/21 - BactériesLeurs milieux de culture modifiés par l'introduction de matériel génétique étranger
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C07K 14/00 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
A01K 67/033 - NÉCESSITÉS COURANTES DE LA VIE ÉLEVAGE; CHASSE; PIÉGEAGE; PÊCHE ÉLEVAGE; AVICULTURE; APICULTURE; PISCICULTURE; PÊCHE; OBTENTION D'ANIMAUX, NON PRÉVUE AILLEURS; NOUVELLES RACES D'ANIMAUX Élevage ou obtention d'animaux, non prévus ailleurs; Nouvelles races d'animaux Élevage ou obtention d'invertébrés; Nouvelles races d'invertébrés
A01N 63/00 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des micro-organismes, des virus, des champignons microscopiques, des animaux ou des substances produites par, ou obtenues à partir de micro-organismes, de virus, de champignons microscopiques ou d'animaux, p. ex. enzymes ou produits de fermentation
41.
Rotating point-spread function (PSF) design for three-dimensional imaging
An optical imaging system having an aperture comprised of a plurality of concentric annuli. The outer radius of each annulus is proportional to the square root of the number of annuli. Each annulus also having an azimuthally linearly increasing phase profile comprising for a given light wavelength. The system also includes a birefringent plate and the aperture and birefringent plate are adapted to jointly encode the full spatial and polarimetric degrees of freedom of a point source.
G02B 27/58 - Optique pour l'apodisation ou la super-résolvanceSystèmes optiques à ouverture synthétisée
G01C 11/02 - Dispositions de prises de vues spécialement adaptées pour la photogrammétrie ou les levers photographiques, p. ex. pour commander le recouvrement des photos
G02B 21/36 - Microscopes aménagés pour la photographie ou la projection
G02B 27/26 - Autres systèmes optiques; Autres appareils optiques pour produire des effets stéréoscopiques ou autres effets de relief comprenant des moyens de polarisation
G02B 27/00 - Systèmes ou appareils optiques non prévus dans aucun des groupes ,
42.
IMMUNOTHERAPY COMPOSITIONS AND METHODS FOR TREATMENT OF TAUOPATHY AND TRANSGENIC MOUSE
This disclosure describes, in one aspect, immunogens effective for treating and/or diagnosing tauopathy, and immunotherapeutic compositions and methods involving those immunogens. Generally, the immunogen includes an antigen presentation component and a microtubule-associated tau protein (MAPT) component linked to at least a portion of the antigen presentation component. This disclosure describes, in another aspect, a transgenic mouse. Generally, the transgenic mouse possesses brain cells that have a polynucleotide that encodes human microtubule-associated protein tau (MAPT). The polynucleotide further exhibits a deletion of at least a portion of endogenous mouse MAPT. The transgenic mouse also includes a forebrain neuron-specific deletion of a polynucleotide that encodes Myeloid Differentiation Primary Response Gene 88 (MyD88). In a further aspect, this disclosure describes a method of producing the transgenic mouse.
Provided is a method for treating a fiber, including: imparting a pattern from a diffraction grating onto a fiber surface. The pattern is capable of diffracting incident polychromatic light into one or more dispersed visible colors, the fiber is not coated and the pattern is imparted directly onto the surface of the fiber.
A45D 19/00 - Dispositifs pour laver les cheveux ou le cuir cheveluDispositifs similaires pour teindre les cheveux
A61K 8/03 - Compositions liquides avec au moins deux couches distinctes
A61K 8/72 - Cosmétiques ou préparations similaires pour la toilette caractérisés par la composition contenant des composés organiques macromoléculaires
A61Q 5/10 - Préparations pour la teinture permanente des cheveux ou des poils
44.
METHODS AND COMPOSITIONS INVOLVING RECOMBINANT HYPOALLERGENS
This disclosure describes recombinant hypoallergens and methods of treating allergy that involve administering a recombinant hypoallergen to a subject. Generally, the recombinant hypoallergen includes at least one amino acid modification compared to a corresponding wildtype allergen. As a result, the recombinant hypoallergen binds to IgE that specifically binds to the allergen, but induces release of histamine from basophils to a degree less than the wildtype allergen.
C07K 14/435 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
C07K 14/415 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant de végétaux
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/16 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
A dynamically reconfigurable framework manages processing applications in order to meet time-varying constraints to select an optimal hardware architecture. The optimal architecture satisfies time-varying constraints including for example, supplied power, required performance, accuracy levels, available bandwidth, and quality of output such as image reconstruction. The process of determining an optimal solution is defined in terms of multi-objective optimization using Pareto-optimal realizations.
G06F 9/455 - ÉmulationInterprétationSimulation de logiciel, p. ex. virtualisation ou émulation des moteurs d’exécution d’applications ou de systèmes d’exploitation
H04N 19/625 - Procédés ou dispositions pour le codage, le décodage, la compression ou la décompression de signaux vidéo numériques utilisant un codage par transformée utilisant une transformée en cosinus discrète
A pliable pressure sensitive sensor device and method of making the same is provided. The sensor includes first and second pliable protective layers, which cover sets of conductive fibers that spatially separated by an electrically conductive pliable layer, which deforms in response to a pressure event. The fiber sets form a grid pattern and are in electrical communication with sets of electrical contacts located in predetermined locations along the fibers. In response to a pressure event in proximity to the contact, the pliable layer deforms and increases the amount of surface area in contact with an electrical contact whereby an electrical resistance at an individual electrical contact decreases in response to the pressure event.
G01L 1/22 - Mesure des forces ou des contraintes, en général en mesurant les variations de la résistance ohmique des matériaux solides ou des fluides conducteurs de l'électricitéMesure des forces ou des contraintes, en général en faisant usage des cellules électrocinétiques, c.-à-d. des cellules contenant un liquide, dans lesquelles un potentiel électrique est produit ou modifié par l'application d'une contrainte en utilisant des jauges de contrainte à résistance
G06F 3/041 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction
G01L 1/18 - Mesure des forces ou des contraintes, en général en utilisant des propriétés des matériaux piézo-résistants, c.-à-d. des matériaux dont la résistance ohmique varie suivant les modifications de la grandeur ou de la direction de la force appliquée au matériau
G01L 1/20 - Mesure des forces ou des contraintes, en général en mesurant les variations de la résistance ohmique des matériaux solides ou des fluides conducteurs de l'électricitéMesure des forces ou des contraintes, en général en faisant usage des cellules électrocinétiques, c.-à-d. des cellules contenant un liquide, dans lesquelles un potentiel électrique est produit ou modifié par l'application d'une contrainte
G01L 1/04 - Mesure des forces ou des contraintes, en général en mesurant la déformation élastique de jauges, p. ex. de ressorts
G06F 3/045 - Numériseurs, p. ex. pour des écrans ou des pavés tactiles, caractérisés par les moyens de transduction utilisant des éléments résistifs, p. ex. une seule surface uniforme ou deux surfaces parallèles mises en contact
B25J 13/08 - Commandes pour manipulateurs au moyens de dispositifs sensibles, p. ex. à la vue ou au toucher
G01L 5/16 - Appareils ou procédés pour la mesure des forces, du travail, de la puissance mécanique ou du couple, spécialement adaptés à des fins spécifiques pour la mesure de plusieurs composantes de la force
47.
RAPID PHENOTYPE TESTS FOR ANTITUBERCULAR DRUG SENSITIVITY AND RESISTANCE
In one embodiment, the invention provides methods of identifying the sensitivity and resistance to therapeutic drug regimens in a subject who suffers from, or who is suspected of suffering from, a Mycobacterium infection, the method comprising administering (1) isotopically labeled Pretomanid and/or Delaminid, or (2) isotopically labeled ethionamide and/or prothionamide, or (3) isotopically labeled pyrazinamide, or (4) isotopically-labeled isoniazid to the subject and thereafter measuring levels in a subject-derived sample of one or more isotopically-labeled markers corresponding to Mycobacterium-actiwated drug metabolites or degradation products, wherein the absence of detectable levels of Mycobacterium-activated drug metabolites or degradation products indicates either that the subject does not suffer from a Mycobacterium infection or suffers from a Mycobacterium infection which is resistant to treatment with the administered drug regimen.
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/72 - Préparations médicinales caractérisées par un aspect particulier à fumer ou inhaler
This disclosure describes, in one aspect, a device for electrochemical quantitation of autoantibodies. Generally, the device includes a housing that defines a plurality of channels and at least two reaction zones. A first reaction zone includes a porous membrane and a first electrode assembly in fluid communication with a first channel. The first reaction zone also includes a first plurality of autoantigens immobilized to the porous membrane. The first electrode assembly is in communication with an amperometric reader. A second reaction zone includes a porous membrane and a second electrode assembly in fluid communication with a second channel. The second reaction zone includes a second plurality of autoantigens immobilized to the porous membrane. The second electrode assembly is in communication with the amperometric reader. Finally, the device includes a source of negative pressure in fluid communication with the first reaction zone and the second reaction zone.
A device includes a body and a rechargeable battery positioned within the body. A solar cell is coupled to the body and in communication with the battery. A connector is coupled to the body and configured to engage a corresponding connector of a fiber optic cable.
The present invention is an apparatus and method for using aggregated loads from a plurality of distributed energy resources to perform a function at a power distribution feeder. The invention includes a plurality of distributed energy resources, wherein at least one distributed energy resource includes a renewable energy resource, a communication network, a control device, a power distribution feeder coupled to the control device, and an energy storage system coupled to the power distribution feeder. The control device sends a signal to the plurality of distributed energy resources via the communication network. The signal is a request to switch a status of one or more of the distributed energy resources if one or more distributed energy resources is within a predetermined condition. Loads from the one or more of the distributed energy resources that switched status are aggregated to perform a function at the power distribution feeder.
The invention relates to compositions including a charged oligo-phenylene ethynylene singlet-oxygen sensitizer and an oppositely-charged surfactant, which show an enhanced biocidal activity relative to a comparable concentration of the oligo-phenylene ethynylene without the oppositely-charged surfactant. The enhancement of biocidal activity is observed with an anionic oligo-phenylene ethynylene in the presence of a cationic surfactant such as TTAB, and with a cationic oligo-phenylene ethynylene in the presence of an anionic surfactant such as SDS.
A61L 2/18 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques des substances liquides
The present invention is an apparatus and method for delivering energy using a renewable resource. The method includes providing a photovoltaic energy source and applying energy storage to the photovoltaic energy source via a battery storage unit. The energy output from the photovoltaic energy source and the battery system is controlled using a battery control system. The battery control system predicts peak load, develops a schedule that includes when to begin discharging power and when to stop discharging power, shifts power to the battery storage unit when excess power is available, and prioritizes the functionality of the battery storage unit and the photovoltaic energy source.
H02J 3/36 - Dispositions pour le transfert de puissance électrique entre réseaux à courant alternatif par l'intermédiaire de haute tension à courant continu
H02J 3/38 - Dispositions pour l’alimentation en parallèle d’un seul réseau, par plusieurs générateurs, convertisseurs ou transformateurs
H02S 40/38 - Moyens de stockage de l’énergie, p. ex. batteries, structurellement associés aux modules PV
53.
TORROIDAL MESOPOROUS SILICA NANOPARTICLES (TMSNPS) AND RELATED PROTOCELLS
In one aspect, the invention provides novel monodisperse, colloidally-stable, torroidal mesoporous silica nanoparticles (TMSNPs) which are synthesized from ellipsoid-shaped mesoporous silica nanoparticles (MSNPs) which are prepared using an ammonia base- catalyzed method under a low surfactant conditions. Significantly, the TMSNPs can be loaded simultaneously with a small molecule active agent, a siRNA, a mRNA, a plasmid and other cargo and can be used in the diagnosis and/or treatment of a variety of disorders, including a cancer, a bacterial infection and/or a viral infection, among others. Related protocells, pharmaceutical compositions and therapeutic and diagnostic methods are also provided.
A61K 9/127 - Vecteurs à bicouches synthétiques, p. ex. liposomes ou liposomes comportant du cholestérol en tant qu’unique agent tensioactif non phosphatidylique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 38/00 - Préparations médicinales contenant des peptides
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p. ex. génie protéique ou administration de médicaments
An atomic layer deposition method is disclosed for preparing polypeptides. The method comprises providing a solid-phase support comprising a reactive amine monolayer in an atomic layer deposition (ALD) chamber. The solid-phase support is contacted with a first protected amino acid substituted with a protecting group by atomic layer deposition, wherein the protecting group is bonded to a non-side chain amino group of the protected amino acid. A carboxylic acid group of the first protected amino acid is reacted with the reactive amine monolayer, thereby coupling the first protected amino acid to the solid- phase support to produce a coupled-product.
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c.-à-d. procédés de dépôt chimique en phase vapeur [CVD] caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
C23C 16/52 - Commande ou régulation du processus de dépôt
55.
Thiophene based oligomers as light activated biocides
A01N 43/82 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec des atomes d'azote et des atomes d'oxygène ou de soufre, comme hétéro-atomes du cycle des cycles à cinq chaînons avec trois hétéro-atomes
A01N 43/10 - Biocides, produits repoussant ou attirant les animaux nuisibles, ou régulateurs de croissance des végétaux, contenant des composés hétérocycliques comportant des cycles avec un ou plusieurs atomes d'oxygène ou de soufre comme uniques hétéro-atomes du cycle avec un hétéro-atome des cycles à cinq chaînons avec le soufre comme hétéro-atome du cycle
C07D 409/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
C07D 417/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes de soufre et d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant au moins trois hétérocycles
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des phénomènes physiques des radiations
A61L 2/16 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contactAccessoires à cet effet utilisant des substances chimiques
56.
DETERMINATION OF ETCHING PARAMETERS FOR PULSED XENON DIFLUORIDE (XEF2) ETCHING OF SILICON USING CHAMBER PRESSURE DATA
A method for determining depletion of an etchant, an etch depth, and an etch rate during an etch of a material such as Si using an etchant such as xenon difluoride (XeF2)in a pulsed etching system in real time measuring pressure within a closed system during the etch. Coupling the pressure data with the knowledge of the chemical reactions allows for the determination of the etching parameters of interest. While the etch of Si using XeF2 is used for demonstration, the method may be generalized to any closed volume system provided there is a net change in number of moles of gaseous species present in the system before and after the reaction.
The invention provides novel antibiotic protocells comprising mesoporous nanoparticles encapsulated within a lipid bi- or multilayer. The nanoparticles have pore sizes and surface chemistries that enable facile adsorption and intracellular presentation of antibiotics which are effective in the treatment of a wide variety of bacterial infections, including F. tularensis, B. pseudomallei and P. aeruginosa-related infections. Related pharmaceutical compositions and methods of treatment are also provided.
This invention relates to compounds and their use as inhibitors or activators of Rab7 GTPase to treat or prevent the onset of Rab 7 GTPase-associated disorders such as neuropathies, cancer, metabolic diseases of bone and lipid storage. The invention is also applicable to infectious diseases where Rab7 is inactivated or its protein-protein interactions are modulated to facilitate intracellular survival of pathogens. The compound described acts as a competitive inhibitor of nucleotide binding and as such also has utility as a scaffold for targeting other small GTPases. In one aspect, methods of treatment of the invention are used to treat or prevent the onset of hereditary sensory neuropathies such as Charcot-Marie-Tooth type 2B disease. Related pharmaceutical compositions, assays, and drug screens are also provided.
The invention provides method of treating a subject suffering from, or at risk of developing, a Mycobacterium infection by administering to the subject a therapeutically-effective amount of isotopically labeled isoniazid and/or ethionamide, or an analog, derivative or prodrug thereof, and exposing the subject to a magnetic field.
Catalyst support materials that are coated with a thin carbon over-layer and methods for making the same are shown and described. In general, a supporting oxide material, which may or may not have a catalytic material already deposited on the surface, is coated with a thin carbon layer.
Novel particular-based pesticides formed from pesticidal agents encapsulated in one or more coatings wherein the coating enhances the pesticidal agent' s ability to control a pest population, and methods for making the same. In various embodiments the pesticidal agent may be a biopesticide and the coating may impart stability, protection from UV radiation and/or other environmental conditions, enhance the attractiveness of the pesticide to the pest, and/or serve to separate two different biologically incompatible pesticides within a mixture.
In one embodiment, the invention provides a new design of nanocarrier compositions that release their therapeutic load specifically at intraperitoneal cancers' site. These nanocarriers are administered intraperitoneally and comprise a plurality of porous nanoparticulates that (a) are loaded with one or more pharmaceutically-active agents alone or in combination with imaging agents thus providing a theranostic value and (b) that are encapsulated by and that support a lipid bilayer which is disrupted upon contact with a reactive oxygen species generated within the environment of the cancer. In other embodiments, the invention provides methods of treatment and pharmaceutical compositions comprising nanocarriers as described herein.
A61K 9/14 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres
A61K 9/22 - Pilules, pastilles ou comprimés du type à libération prolongée ou discontinue
A61K 47/48 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. supports, additifs inertes l'ingrédient non actif étant chimiquement lié à l'ingrédient actif, p.ex. conjugués polymère-médicament
A61K 47/30 - Composés macromoléculaires organiques ou inorganiques, p. ex. polyphosphates inorganiques
In a fuel cell including an electrolyte layer allowing an anion component to migrate, and a fuel-side electrode and an oxygen-side electrode arranged to face each other while sandwiching the electrolyte layer, the oxygen-side electrode contains a first catalyst containing a first transition metal and polypyrrole, and a second catalyst containing a second transition metal and a porphyrin ring-containing compound so that the mixing ratio of the first catalyst relative to 100 parts by mass of the total amount of the first catalyst and the second catalyst is more than 10 parts by mass, and below 90 parts by mass.
This invention relates generally to integrin ligand discovery and to a method of integrin ligand discovery base upon induction of ligand-induced epitopes. Such ligands have the potential to be active agent as anti-inflammatory, anti-angiogenesis and/or anti-thrombotic agents and for the treatment of integrin mediated diseases and/or conditions.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
A61K 31/36 - Composés contenant des groupes méthylènedioxyphényle, p. ex. sésamine
A method of calculating radiation fluence and energy deposition distributions on a networked virtual computational cluster is presented. With this method, complex Monte Carlo simulations that require expansive equipment, personnel, and financial resources can be done efficiently and inexpensively by hospitals and clinics requiring radiation therapy dose calculations.
G06F 19/00 - Équipement ou méthodes de traitement de données ou de calcul numérique, spécialement adaptés à des applications spécifiques (spécialement adaptés à des fonctions spécifiques G06F 17/00;systèmes ou méthodes de traitement de données spécialement adaptés à des fins administratives, commerciales, financières, de gestion, de surveillance ou de prévision G06Q;informatique médicale G16H)
G06F 15/16 - Associations de plusieurs calculateurs numériques comportant chacun au moins une unité arithmétique, une unité programme et un registre, p. ex. pour le traitement simultané de plusieurs programmes
Disclosed is a fuel cell including: an electrolyte layer which can move an anionic component; and a fuel-side electrode and an oxygen-side electrode which are arranged opposite one another on either side of the electrolyte layer, wherein a first catalyst including a first transition metal and polypyrrole and a second catalyst including a second transition metal and a porphyrin ring-containing compound are included in the oxygen-side electrode in such a way that the mixing ratio of the first catalyst exceeds 10 parts by mass but is less than 90 parts by mass with respect to 100 parts by mass of the total amount of the first catalyst and the second catalyst.
A dry powder delivery device may be configured to provide micronized dry powder particles to airways of a user. The device may include a cylindrical container delimiting a chamber containing at least one magnetically- responsive object, a motor external to said chamber, a magnet external to the chamber and rotatably coupled with the motor, and an outflow member configured to direct airflow to a user. The magnetically-responsive object may be coated with micronized dry powder particles, and the motor may be operable to rotate the magnet about an axis. Rotation of the magnet creates a magnetic field that causes the magnetically-responsive object to move in response to the magnetic field and collide with a side wall of the container to deaggregate the dry powder particles and aerosolize the dry powder in the chamber.
A61M 11/02 - Pulvérisateurs ou vaporisateurs spécialement destinés à des usages médicaux agissant par pression d'air sur les liquides à pulvériser ou vaporiser
A61J 1/05 - Récipients spécialement adaptés à des fins médicales ou pharmaceutiques pour recueillir, stocker ou administrer du sang, du plasma ou des liquides à usage médical
68.
PRODUCTION OF CELLULASES AND HEMICELLULASES IN ALGAL BIOFUEL FEEDSTOCKS
A method for producing hemicellulase and cellulase for use in processing cellulosic materials for biofuel production. The method involves transforming algal feedstock to express hemicellulase and cellulase and then collecting hemicellulase and cellulase that has been secreted into a culture medium by the algae. The method may further involve transforming the algal feedstock to express other recombinant products and/or processing the alga feedstock to produce biofuels.
A photoacoustic imaging device includes an array of light sources configured and arranged to illuminate a target region and an array of ultrasonic transducers between the array of light sources and the target region. The array of transducers may be fixedly coupled to the array of light sources, and the array of ultrasonic transducers may be configured and arranged to receive ultrasound transmissions from the target region.
G01N 29/00 - Recherche ou analyse des matériaux par l'emploi d'ondes ultrasonores, sonores ou infrasonoresVisualisation de l'intérieur d'objets par transmission d'ondes ultrasonores ou sonores à travers l'objet
A61B 8/00 - Diagnostic utilisant des ondes ultrasonores, sonores ou infrasonores
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
This invention relates to novel cancer treatment compositions and associated therapeutic methods. More particularly, this invention relates in part to small chemical bifunctional inhibitors of DNA replication and repair proteins Metnase and/or Intnase (also termed Gypsy Integrase, Gypsy Integrease-1, Gypsy Retransposon Integrase 1, or GIN-I) that simultaneously damage DNA, and to a therapeutic method that utilizes the inhibitors to increase the effectiveness of cancer treatment protocols, including radiation therapy. In preferred embodiments, compounds, compositions and methods of treatment of the invention are used to treat a patient suffering from leukemia (e.g. acute myeloid leukemia (AML) and related cancers. In certain aspects of such treatments, compounds, compositions and methods of treatment of the invention are administered as a monotherapy (in some cases, to patients who have exhibited resistance to Topo IIalpha inhibitors such as VP- 16), or are co-administered with a Topo IIalpha inhibitor or other anti-cancer agents as otherwise described herein or in combination with radiation therapy.
C07D 215/233 - Atomes d'oxygène liés en position 2 ou 4 un seul atome d'oxygène qui est lié en position 4
C07D 401/04 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une liaison directe de chaînon cyclique à chaînon cyclique
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
A system and methods that generates a physical unclonable function ("PUF") security key for an integrated circuit ("IC") through use of equivalent resistance variations in the power distribution system ("PDS") to mitigate the vulnerability of security keys to threats including cloning, misappropriation and unauthorized use.
G06F 21/73 - Protection de composants spécifiques internes ou périphériques, où la protection d'un composant mène à la protection de tout le calculateur pour assurer la sécurité du calcul ou du traitement de l’information par création ou détermination de l’identification de la machine, p. ex. numéros de série
The present invention is directed to novel non-invasive diagnostic tools/compounds to image cancers, especially, melanoma, including metastatic melanoma in vivo. The present compounds exhibit enhanced uptake in cancerous cells and tissue and decreased renal uptake in kidney, evidencing favorable pharmacokinetics of compounds of the present invention. The compounds according to the present invention represent an advance in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention are also useful for initiating therapy for melanoma as well as monitor patients' response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compounds according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
Generic rights expression language allowing interoperability across different computing environments including resource usage of different applications. A formal framework for usage management provides scaffolding upon which interoperable usage management systems can be built. Certain features of the framework are standardized, such as the operational semantics, including areas free of standards that necessitate choice and innovation to achieve a balance of flexibility and usability for interoperability in usage management systems.
D06M 14/02 - Polymérisation par greffage de monomères, contenant des liaisons non saturées carbone-carbone, sur des fibres, fils, filés, tissus ou articles fibreux faits de ces matières sur des matières d'origine naturelle
D06M 15/37 - Composés macromoléculaires obtenus par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone
D06M 11/32 - Traitement des fibres, fils, filés, tissus ou des articles fibreux faits de ces matières, avec des substances inorganiques ou leurs complexesUn tel traitement combiné avec un traitement mécanique, p. ex. mercerisage avec de l'oxygène, de l'ozone, des ozonides, des oxydes, des hydroxydes ou des percomposésSels dérivés d'anions avec une liaison élément amphotère-oxygène
D06M 14/04 - Polymérisation par greffage de monomères, contenant des liaisons non saturées carbone-carbone, sur des fibres, fils, filés, tissus ou articles fibreux faits de ces matières sur des matières d'origine naturelle d'origine végétale, p. ex. cellulose ou ses dérivés
75.
SYSTEM AND METHODS PHOTON-BASED RADIOTHERAPY AND RADIOSURGERY DELIVERY
Photon-based radiosurgery is widely used for treating local and regional tumors. The key to improving the quality of radiosurgery is to increase the dose falloff rate from high dose regions inside the tumor to low dose regions of nearby healthy tissues and structures. Dynamic photon painting (DPP) further increases dose falloff rate by treating a target by moving a beam source along a dynamic trajectory, where the speed, direction and even dose rate of the beam source change constantly during irradiation. DPP creates dose gradient that rivals proton Bragg Peak and outperforms Gamma Knife® radiosurgery.
A61N 5/10 - RadiothérapieTraitement aux rayons gammaTraitement par irradiation de particules
A61B 6/00 - Appareils ou dispositifs pour le diagnostic par radiationsAppareils ou dispositifs pour le diagnostic par radiations combinés avec un équipement de thérapie par radiations
A61B 5/05 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiquesMesure utilisant des micro-ondes ou des ondes radio
76.
ARG-GLY-ASP-CONJUGATED ALPHA-MELANOCYTE STIMULATING HORMONE HYBRID PEPTIDE FOR USE IN DIAGNOSING AND TREATING MELANOMA, INCLUDING METASTATIC MELANOMA AND METHODS RELATED TO SAME
The present invention is directed to novel non-invasive diagnostic and therapeutic tools/compounds comprising a hybride cyclic peptide which utilizes a cyclic peptide chelating group wherein the compound binds to a MSH receptor to image and treat cancers, especially, melanoma, including metastatic melanoma in vivo. The present invention represents a clear advance in the art which presently relies on tissue biopsy for diagnoses of these cancers. The novel imaging probes are capable of detecting cancerous melanoma cells, as well as their metastatic spread in tissues. This represents a quantum step forward in the diagnosis and treatment of melanoma, including metastatic melanoma using non-invasive molecular imaging techniques. The novel probes of the present invention will also be useful to initiate therapy for melanoma as well as monitor patients response to chemotherapy treatments and other interventions or therapies used in the treatment of melanoma/metastatic melanoma. Compound according to the present invention may be used as diagnostic tools for a number of conditions and diseases states as well as therapeutic agents for treating such conditions and disease states.
A method of controlling fouling of a reverse osmosis membrane disposed in an aqueous medium by an inorganic foulant involves providing a fouling control agent comprising an acidic polysaccharide such as alginic acid fouling control agent dissolved in the aqueous medium in an amount effective to reduce, reverse, or prevent fouling by an inorganic foulant.
The invention provides direct processes and related catalysts for the syntheses of trisubstituted chiral pyrrolidines, piperidines, tetrahydrothiophenes, and thianes by highly enantio- and diastereoselective cascade Michael-Michael reaction of α, β-unsaturatedaldehydes with /ra/25-γ-protected amino α, β-unsaturated esters.
C07D 207/335 - Radicaux substitués par des atomes d'azote ne faisant pas partie d'un radical nitro
C07D 207/337 - Radicaux substitués par des atomes de carbone comportant trois liaisons à des hétéro-atomes avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile
C07D 207/10 - Composés hétérocycliques contenant des cycles à cinq chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle avec uniquement des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle ne comportant pas de liaison double entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
79.
A VIRAL NUCLEOCAPSID PROTEIN AS A MULTIFUNCTIONAL TRANSLATION INITIATION FACTOR AND INCREASED PROTEIN AND POLYPEPTIDE PRODUCTION USING SAME
The present invention is directed to a system to significantly increase the expression of genes of interest, and in particular proteins and polypeptide products. Expression of hantavirus nucleocapsid protein (N) by itself results in augmented translational expression of diverse genes. The mechanism of this augmentation relies on the ability of N to replace the cellular cap binding complex to attain more efficient translation initiation- the result being great mRNA production and greater protein/polypeptide production. The inventors have also recently found that inclusion of a 5' untranslated leader region (viral UTR) from a viral RNA, in conjunction with N, leads to even more robust expression. This mechanism appears to involve recognition of the viral UTR by the N to provide even more robust protein production. Thus, a general strategy for expression of any gene would be to generate significant quantities of mRNA containing the viral UTR from a strong promoter, and then to allow translation of mRNA of a gene product in the presence of N. Even a modest increase in the production of commercially desirable proteins is a goal in industry.
A lateral flow device includes a porous medium layer having a two-dimensional shape in plan view that is capable of supporting near-constant velocity capillary-driven fluid flow and can be combined with electrodes in a manner to achieve to achieve electrokinetic molecule separation.
An aerosol-assisted method for synthesis of nanostructured metallic electrocatalysts and the electrocatalysts formed thereby. The electrocatalyst may be formed from metals such as, but not limited to, platinum, platinum group metals, and binary and tertiary compositions thereof such as, for example, platinum-ruthenium and platinum-tin. The resulting unsupported electrocatalyst is homogenous and highly disperse.
The present invention relates to the use of isotopically labeled derivatives of isoniazid, ethionamide and related compounds as effective therapy for the treatment of mycobacterial diseases, including Mycobacterium tuberculosis.
A61K 31/4409 - Pyridines non condenséesLeurs dérivés hydrogénés substituées uniquement en position 4, p. ex. isoniazide, iproniazide
A61K 31/44 - Pyridines non condenséesLeurs dérivés hydrogénés
C07D 213/127 - Préparation à partir de composés renfermant des cycles pyridiniques
C07D 213/16 - Composés hétérocycliques contenant des cycles à six chaînons, non condensés avec d'autres cycles, ne comportant qu'un atome d'azote comme unique hétéro-atome du cycle et avec au moins trois doubles liaisons entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques comportant trois liaisons doubles ne comportant pas de liaison entre l'atome d'azote du cycle et un chaînon non cyclique ou ne comportant que des atomes d'hydrogène ou de carbone liés directement à l'atome d'azote du cycle contenant uniquement des atomes d'hydrogène et de carbone en plus de l'atome d'azote du cycle ne contenant qu'un cycle pyridique
The present invention includes a laser amplifier and a method of making the same. The laser amplifier of the present invention includes a gain medium layer having a first index of refraction, and a coupling layer optically coupled to the gain medium. In the various embodiments described herein, the coupling layer can have a second index of refraction less than the first index of refraction. The laser amplifier described herein can also include an evanescent layer disposed between the gain medium and the coupling layer. The evanescent layer can have a third index of refraction less than the second index of refraction. The laser amplifier provides high power, efficient laser resonance through frustrated total internal reflection and total internal reflection while simultaneously providing for the minimization of waste heat in the gain medium layer.
H01S 3/00 - Lasers, c.-à-d. dispositifs utilisant l'émission stimulée de rayonnement électromagnétique dans la gamme de l’infrarouge, du visible ou de l’ultraviolet
84.
System and method for reduction of speckle noise in an image
The present invention includes methods for the reduction of speckle noise in an image and methods for segmenting an image. Each of the methods disclosed herein includes steps for analyzing the uniformity of a pixel within a plurality of pixels forming a portion of the image and, based on the uniformity of the intensity of the plurality of pixels, adjusting and/or replacing the pixel in order to produce a speckle-noise reduced image, a segmented image, or a segmented and speckle-noise reduced image. The methods of the present invention can employ for example conditional probability density functions, nonlinear estimator functions, convex energy functions and simulated annealing algorithms in the performance of their respective steps.
Apparatus and methods for establishing a secret key to encrypt and share data using quantum signals represented by an equiangular spherical code and using classical signals in authenticating the key.
brevets
